How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?

Neurochemistry International

Volumn 50, Issue 2, 2007, Pages 291-301

  Kondziella, Daniel ^a,b   Brenner, Eiliv ^a   Eyjolfsson, Elvar M ^a   Sonnewald, Ursula ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

13C nuclear magnetic resonance spectroscopy; Astrocytes; Dopamine; Glutamate; MK 801; Neurons; NMDA glutamate antagonists; Schizophrenia

Indexed keywords

ACETIC ACID; AMPHETAMINE; DIZOCILPINE; GLUCOSE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ASTROCYTE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL INTERACTION; CITRIC ACID CYCLE; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; GABAERGIC TRANSMISSION; GLIA CELL; HOMEOSTASIS; HUMAN; MENTAL DETERIORATION; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; DIZOCILPINE MALEATE; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; NEUROGLIA; NEURONS; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA;

ANIMALIA;

EID: 33846238600     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.09.006     Document Type: Review

References (74)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155 (1998) 761-767
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L., Weiss R., Cooper T.B., Mann J.J., Van Heertum R., and Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97 (2000) 8104-8109
3. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van Heertum R., Gorman J.M., and Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22 (2002) 3708-3719
4. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., and Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 54 (1997) 959-965
5. Berl S., and Clarke D.D. Compartmentation of amino acid metabolism. In: Lajtha A. (Ed). Handbook of Neurochemistry vol. 2 (1969), Plenum Press, New York 447-472
6. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelmann W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentration: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94 (1997) 2569-2574
7. Brenner E., Kondziella D., Haberg A., and Sonnewald U. Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK-801. J. Neurochem. 94 (2005) 1594-1603
8. Burbaeva G.S., Boksha I.S., Turishcheva M.S., Vorobyeva E.A., Savushkina O.K., and Tereshkina E.B. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 675-680
9. Carlsson A. A paradigm shift in brain research. Science 294 (2001) 1021-1024
10. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychology 39 Suppl. 1 (2006) 10-14
11. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
12. Carlsson M.L., Carlsson A., and Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem. 11 (2004) 267-277
13. Collins R.C., and Olney J.W. Focal cortical seizures cause distant thalamic lesions. Science 218 (1982) 177-179
14. Cotter D.R., Pariante C.M., and Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull. 55 (2001) 585-595
15. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 (2001) 1-105
16. de Bartolomeis A., Fiore G., and Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr. Pharm. Des. 11 (2005) 3561-3594
17. Eyjolfsson E., Brenner E., Kondziella D., and Sonnewald U. Repeated injection of MK801: An animal model of schizophrenia?. Neurochem. Int. 48 (2006) 541-546
18. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann. NY Acad. Sci. 1003 (2003) 119-130
19. Farber N.B., Wozniak D.F., Price M.T., Labrueyere J., Huss J., St Peter H., and Olney J.W. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol. Psychiatry 12 (1995) 788-796
20. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7 (2002) 32-43
21. Farber N.B., Jiang X.P., Heinkel C., and Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry 7 (2002) 726-733
22. Gill R., Foster A.C., and Woodruff G.N. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7 (1987) 3343-3349
23. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
24. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
25. Heresco-Levy U., and Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 66 (2004) 89-96
26. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 55 (2004) 165-171
27. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., and Ermilov M. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57 (2005) 577-585
28. Hertz L. Functional interactions between neurons and astrocytes. I. Turnover and metabolism of putative amino acid transmitters. Prog. Neurobiol. 13 (1979) 277-323
29. Horvath Z.C., Czopf J., and Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res. 753 (1997) 181-195
30. Hyman S.E., and Fenton W.S. Medicine. What are the right targets for psychopharmacology?. Science 299 (2003) 350-351
31. Jann M.W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24 (2004) 1759-1783
32. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., and Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4 (2001) 385-391
33. Johnston-Wilson N., Sims C.D., Hoffman J.P., Anderson L., Shore A.D., Torrey E.F., and Yolken R. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder and major depressive disorder. Mol. Psychiatry 5 (2000) 142-149
34. Kegeles L.S., Zea-Ponce Y., Abi-Dargham A., Rodenhiser J., Wang T., Weiss R., Van Heertum R.L., Mann J.J., and Laruelle M. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31 (1999) 302-308
35. Kondziella D., Brenner E., Evjolfsson E.M., Markinhuhta K.R., Carlsson M.L., and Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacol. 31 (2006) 1880-1887
36. Kosenko E., Llansola M., Montoliu C., Monfort P., Rodrigo R., Hernandez-Viadel M., Erceg S., Sanchez-Perez A.M., and Felipo V. Glutamine synthetase activity and glutamine content in brain: modulation by NMDA receptors and nitric oxide. Neurochem. Int. 43 (2003) 493-499
37. Kvamme E., Roberg B., and Torgner I.A. Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain. Neurochem. Res. 25 (2000) 1407-1419
38. Laruelle M., Kegeles L.S., and Abi-Dhargham A. Glutamate, dopamine and schizophrenia. From pathophysiology to treatment. Ann. N.Y. Acad. Sci. 1003 (2003) 138-158
39. Loscher W., and Honack D. Anticonvulsant and behavioral effects of two novel competitive N-Methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256 (1991) 432-440
40. Loubinoux I., Meric P., Borredon J., Correze J.L., Gillet B., Beloeil J.C., Tiffon B., Mispelter J., Lhoste J.M., and Jacques S. Cerebral metabolic changes induced by MK-801: a 1D (phosphorus and proton) and 2D (proton) in vivo NMR spectroscopy study. Brain Res. 643 (1994) 115-124
41. Matute C., Melone M., Vallejo-Illarramendi A., and Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49 (2005) 451-455
42. Melone M., Bragina L., and Conti F. Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. Mol. Psychiatry 8 (2003) 12-13
43. Millan M.J. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179 (2005) 30-53
44. Nanitsos E.K., Nguyen K.T.D., Stastny F., and Balcar V.J. Glutamatergic hypothesis of schizophrenia: involvement of Na+/Kdependant glutamate transport. J. Biomed. Sci. 12 (2005) 975-984
45. Niizato K., Iritani S., Ikeda K., and Arai H. Astroglial function of schizophrenic brain: a study using lobotomized brain. Clin. Neurosci. Neuropathol. 12 (2001) 1457-1460
46. Ogita K., Okuda H., Yamamoto Y., Nishiyama N., and Yoneda Y. In vivo neuroprotective role of NMDA receptors against kainate-induced excitotoxicity in murine hippocampal pyrimidal neurons. J. Neurochem. 85 (2003) 199-209
47. Ohno M., and Watanabe S. Enhanced N-methyl-d-aspartate function reverses working memory failure induced by blockade of group 1 metabotropic glutamate receptors in the rat hippocampus. Neurosci. Lett. 240 (1998) 37-40
48. Ongur D., Drevets W.C., and Price J. Glial reduction in the subungual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 95 (1998) 13290-13295
49. 13C MR spectroscopy study of lactate as substrate for rat brain. Dev. Neurosci. 22 (2000) 429-436
50. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Melter H., Overholser C., and Stockmeier C.A. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 57 (2002) 127-138
51. Ransom B., Behar T., and Nedergaard M. New roles for astrocytes (stars at last). Trends Neurosci. 10 (2003) 520-522
52. Rothermundt M., Ponath G., Glaser T., and Hetzel G. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29 (2004) 1004-1011
53. Rothermundt M., Falkai P., Ponath G., Abel S., Bürkle H., Diedrich M., Hetzel G., Peters M., Siegmund A., Pedersen A., Maier W., Schramm J., Suslow T., Ohrmann P., and Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 9 (2004) 897-899
54. Rujescu, D., Bender, A., Keck, M., Hartmann, A.M., Ohl, F., Raeder, H., Giegling, I., Genius, J., McCarley, R.W., Moller, H.J., Grunze H., 2006. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry, [Epub ahead of print].
55. Rung J.P., Carlsson A., Ryden Markinhuhta K., and Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 29 (2005) 827-832
56. Schipke C.G., Ohlemeyer C., Matyash M., Nolte C., Kettenmann H., and Kirchhoff F. Astrocytes of the mouse neocortex express functional N-methyl-d-aspartate receptors. FASEB J. 15 (2001) 1270-1272
57. Schneider J.S., Tinker J.P., Van Velson M., and Giardiniere M. Effects of partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res. 860 (2000) 190-194
58. Schroeter M.L., Abdul-Khaliq H., Frühauf S., Höhne R., Schick G., Diefenbacher A., and Blasig I.E. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res. 62 (2003) 231-236
59. Selemon L.D., Lidow M.S., and Goldman-Rakic P.S. Increased volume and glial density in premate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol. Psychiatry 46 (1999) 161-172
60. Shank R.P., Bennett G.S., Freytag S.O., and Campbell G.L. Pyruvate carboxylase: an astrocytic-specific enzyme implicated in the replenishment of amino acids neurotransmitter pool. Brain Res. 329 (1985) 362-367
61. Sonnewald U., and Kondziella D. Neuronal glial interaction in different neurological diseases studied by ex vivo 13 C NMR spectroscopy. NMR Biomed. 16 (2003) 424-429
62. Tarzi F.I. Long-term effects of olanzapine, risperidone and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306 (2003) 1145-1151
63. Taylor A., McLean M., Morris P., and Bachelard H. Approaches to studies on neuronal/glial relationships by 13 C-MRS Analysis. Dev. Neurosci. 18 (1996) 434-442
64. Theberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159 (2002) 1944-1946
65. Theberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160 (2003) 2231-2233
66. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 165-179
67. Uranova N.A., Casanova M.F., DeVaughn N.M., Orlovskaya D.D., and Denisov D. Ultrastructural alterations of synaptic contacts and astrocytes in post-mortem caudate nucleus of schizophrenic patients. Schizophr. Res. 22 (1996) 81-83
68. Vallejo-Illarramendi A., Torre-Ramos M., Melone M., Conti F., and Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50 (2005) 276-279
69. Waniewski R.A., and Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J. Neurosci. 18 (1998) 5225-5233
70. Webster M.J., Johnston-Wilson N., Nagata K., and Yolken R.H. Alterations in the expression of phosphorylated glial fibrillary acidic protein in the frontal cortex of individuals with schizophrenia, bipolar disorder and depression. Schizophr. Res. 41 (2000) 106
71. Webster M.J., Johnston-Wilson N., Inagata M., Nagata K., and Yolken R.H. Immunhistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder and depression. Brain Biol. Immunol. 15 (2001) 388-400
72. Webster M.J., O'Grady J., Kleinman J.E., and Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133 (2005) 453-461
73. Wozniak D.F., Dikranian K., Ishimaru M.J., Nardi A., Corso T.D., Tenkova T., Olney J.W., and Fix A.S. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol. Dis. 5 (1998) 305-322
74. Yu A.C.H., Drejer J., Hertz L., and Schousboe A. Pyruvate carboxylase activity in primary cultures of astrocytes and neurons. J. Neurochem. 41 (1983) 1484-1487